128 related articles for article (PubMed ID: 38084867)
21. Baricitinib for alopecia areata.
Imran H; Hoda F; Shakil F
J Pak Med Assoc; 2023 May; 73(5):1172. PubMed ID: 37218276
[No Abstract] [Full Text] [Related]
22. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis.
Delvino P; Bartoletti A; Monti S; Biglia A; Montecucco C; Carducci M; Ripamonti G; Cavagna L
Rheumatology (Oxford); 2020 Dec; 59(12):e125-e127. PubMed ID: 32353871
[No Abstract] [Full Text] [Related]
23. Inhibition of Progression of Acrodermatitis Continua of Hallopeau With Baricitinib.
Han GM; Yang WS; Yang B
JAMA Dermatol; 2021 Apr; 157(4):466-468. PubMed ID: 33656520
[No Abstract] [Full Text] [Related]
24. Baricitinib: A chance to treat COVID-19?
Lo Caputo S; Corso G; Clerici M; Santantonio TA
J Med Virol; 2020 Nov; 92(11):2343-2344. PubMed ID: 32437019
[No Abstract] [Full Text] [Related]
25. Comment on ‘Treatment of moderate-to-severe alopecia areata in preadolescent children with baricitinib’: authors’ reply.
Asfour L; Bokhari L; Bhoyrul B; Eisman S; Moussa A; Rees H; Sinclair RD
Br J Dermatol; 2023 Dec; 190(1):136-137. PubMed ID: 37596774
[No Abstract] [Full Text] [Related]
26. Efficacy and safety of the oral Janus kinase inhibitor baricitinib 
